EB Clinical Research Consortium (EBCRC) Grants
EB Clinical Research Consortium Grants from EB Research Partnership support clinical research to develop and advance new therapies for Epidermolysis Bullosa.
Funder: EB Research Partnership
Due Dates: September 11, 2026 (full application deadline)
Funding Amounts: Amount varies; subject to EBRP policy, 5% cap on indirect costs; multi-year, project-based support possible.
Summary: Funds clinical research conducted by EB Clinical Research Consortium (EBCRC) site members to advance therapies for Epidermolysis Bullosa.
Key Information: Only EBCRC site members are eligible; applications must be for EBCRC-related projects.
Description
The EB Clinical Research Consortium (EBCRC) Grants, administered by the EB Research Partnership (EBRP), are designed to support clinical research activities conducted by members of the EB Clinical Research Consortium. These grants are part of EBRP’s 2026 grant cycle and are specifically allocated for projects that advance the development of therapies and interventions for Epidermolysis Bullosa (EB). The program operates under EBRP’s venture philanthropy model, aiming to fund research that can lead directly to commercially feasible products and therapies. All funded projects must align with EBRP’s mission to accelerate impactful outcomes in EB research and are governed by EBRP’s established grant guidelines and policies.
